Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes
|
Jan 2017
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
|
Jan 2017
|
Cancer
|
myelodysplastic syndromes (MDS)
|
How I treat acquired aplastic anemia
|
Jan 2017
|
Blood
|
aplastic anemia
|
Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece
|
Jan 2017
|
Hematology
|
myelodysplastic syndromes (MDS)
|
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
|
Jan 2017
|
J Hematol Oncol
|
aplastic anemia
|
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium
|
Jan 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Jan 2017
|
Asia Pac J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
|
Jan 2017
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years
|
Jan 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Feb 2017
|
JAMA Oncol
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|